SEC Filing Record

Offering Amount

$70.7M

Strategy

Hedge

Exemption

06b

Date Filed

Jun 10, 2026

0001932582-26-000001

View on SEC EDGAR →

37A Read

The dual LLC structure—with both a USVI and mainland Delaware entity listed as co-GPs—signals a tax-efficient setup common in life sciences hedge funds, likely designed to accommodate both U.S. and non-U.S. limited partners while centralizing management through Driehaus Capital Management LLC.

The five-person named GP roster (three individuals plus two entities) and 06b exemption indicate Driehaus is operating this as a closed raise to existing relationships rather than broadening distribution, which is typical for a specialized life sciences strategy that may not have achieved institutional scale or third-party marketing capability.

Filing an amendment to a life sciences fund in mid-2026 aligns with biotech sector rebalancing after the 2023–2025 downturn and IP/patent-heavy deal flow improving in small-cap therapeutics and diagnostics—a window where hedge managers with life sciences theses are recapitalizing to deploy into distressed or secondary opportunities.

Verify whether this is a continuation vehicle or a first-time raise from Driehaus in life sciences, since no prior EDGAR filings appear under this manager: a true debut strategy carries different key-man and operational risk than a follow-on fund, and the absence of prior Form ADV or SEC history should be confirmed independently.

Full analysis (GP structure, exemption breakdown, and market context) is available to Pro members.

Unlock Pro · $29/month → Sign in

Principals

General Partners & Executives

n/a Driehaus Capital Management (USVI) LLC n/a Driehaus Capital Management LLC Stephen Weber Janet McWilliams Robert Kurinsky

Driehaus Life Sciences (QP) Fund, L.P.